期刊
ANNALS OF ONCOLOGY
卷 23, 期 9, 页码 2374-2380出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdr627
关键词
cerebrospinal fluid; meningeal dissemination; primary CNS lymphoma
类别
资金
- German Cancer Aid [70-2838-Th 2]
- Kompetenznetz Maligne Lymphome Forderung Teilprojekt 2.3 (Meningeosis bei PCNSL)
We evaluated the frequency and prognostic impact of meningeal dissemination (MD) in immunocompetent adult patients with primary central nervous system lymphoma treated in a randomized phase III trial. MD was evaluated at study entry and defined by lymphoma proof in the meningeal compartment detected by at least one of the following methods: cerebrospinal fluid (CSF) cytomorphology, detection of clonal B cells by IgH PCR in CSF or contrast enhancement of the leptomeninges on magnetic resonance imaging (MRI). Data on MD were available in 415 patients, of those, MD was detected in 65 (15.7%): in 44/361 (12.2%) by CSF cytomorphology, in 16/152 (10.5%) by PCR and in 17/415 (4.1%) by MRI. Major patients' characteristics and therapy did not significantly differ between patients with MD (MD+) versus those without MD (MD-). There was a significant correlation of MD with CSF pleocytosis (> 5/mu l; P < 0.0001), but no correlation with CSF protein elevation (> 45 mg/dl). Median progression-free survival was 6.7 months [95% confidence interval (CI) 0-14.5] in MD+ and 8.3 months (5.7-10.8) in MD- patients (P = 0.95); median overall survival was 21.5 months (95% CI 16.8-26.1) and 24.9 months (17.5-32.3), respectively (P = 0.98). MD was detected infrequently and had no impact on outcome in this trial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据